Show simple item record

dc.contributor.authorColeman, C.M.
dc.contributor.authorTaylor, J.K.
dc.contributor.authorFrieman, M.B.
dc.date.accessioned2020-03-27T15:13:17Z
dc.date.available2020-03-27T15:13:17Z
dc.date.issued2014
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84900416594&doi=10.1016%2fj.vaccine.2014.04.016&partnerID=40&md5=5ce359dd4124453063200af4939f4550
dc.identifier.urihttp://hdl.handle.net/10713/12418
dc.description.abstractDevelopment of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.en_US
dc.description.sponsorshipThis project has been funded in part by a supplement to NIH RO1 AI095569.en_US
dc.description.urihttps://doi.org/10.1016/j.vaccine.2014.04.016en_US
dc.language.isoen_USen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofVaccine
dc.subjectMiddle East Respiratory Syndrome Coronavirusen_US
dc.subjectNeutralizing antibodyen_US
dc.subjectSevere Acute Respiratory Syndrome Coronavirusen_US
dc.subjectVaccineen_US
dc.subjectMERS-CoVen_US
dc.subjectSARS-CoVen_US
dc.subject.meshSARS Virusen_US
dc.titlePurified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in miceen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.vaccine.2014.04.016
dc.identifier.pmid24736006
dc.identifier.ispublishedNo


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record